PL1842550T3 - Kompozycja do indukowania immunotolerancji - Google Patents

Kompozycja do indukowania immunotolerancji

Info

Publication number
PL1842550T3
PL1842550T3 PL07105399T PL07105399T PL1842550T3 PL 1842550 T3 PL1842550 T3 PL 1842550T3 PL 07105399 T PL07105399 T PL 07105399T PL 07105399 T PL07105399 T PL 07105399T PL 1842550 T3 PL1842550 T3 PL 1842550T3
Authority
PL
Poland
Prior art keywords
composition
inducing immunotolerance
immunotolerance
inducing
Prior art date
Application number
PL07105399T
Other languages
English (en)
Inventor
Oosterhout Antonius Josephus Maria Van
Martien Lukas Kapsenberg
Frank Reinoud Weller
Yousef Al-Madane Taher
Esch Elisabeth Catharina Adriana Maria Lobato-Van
Joost Lambert Max Vissers
Original Assignee
Hal Allergy Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hal Allergy Holding B V filed Critical Hal Allergy Holding B V
Publication of PL1842550T3 publication Critical patent/PL1842550T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
PL07105399T 2003-03-28 2004-03-25 Kompozycja do indukowania immunotolerancji PL1842550T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03075909A EP1462111A1 (en) 2003-03-28 2003-03-28 Composition for inducing immunotolerance
EP04723429A EP1608391A2 (en) 2003-03-28 2004-03-25 Composition for inducing of immunotolerance
EP07105399A EP1842550B1 (en) 2003-03-28 2004-03-25 Composition for inducing immunotolerance

Publications (1)

Publication Number Publication Date
PL1842550T3 true PL1842550T3 (pl) 2013-06-28

Family

ID=32798967

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07105399T PL1842550T3 (pl) 2003-03-28 2004-03-25 Kompozycja do indukowania immunotolerancji

Country Status (8)

Country Link
US (1) US20060057154A1 (pl)
EP (4) EP1462111A1 (pl)
CA (1) CA2518793A1 (pl)
DK (1) DK1842550T3 (pl)
ES (1) ES2403074T3 (pl)
PL (1) PL1842550T3 (pl)
PT (1) PT1842550E (pl)
WO (1) WO2004084927A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340505A3 (en) * 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US7378509B2 (en) * 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
EP1799271A4 (en) * 2004-09-21 2010-05-05 Anesiva Inc ADMINISTRATION OF POLYNUCLEOTIDES
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
EP1723965A1 (en) * 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
CN101646418B (zh) * 2006-10-12 2013-07-17 昆士兰大学 调节免疫应答的组合物和方法
WO2008080195A1 (en) * 2006-12-29 2008-07-10 The University Of Queensland Compositions and methods for treating or preventing unwanted immune responses
WO2008150899A1 (en) * 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2012064657A1 (en) * 2010-11-08 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Serum amyloid a (saa) overrides regulatory t cells (treg) anergy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203535D0 (en) * 1992-02-19 1992-04-08 Leo Pharm Prod Ltd Novel treatment iii
EP0759782A1 (en) * 1994-05-26 1997-03-05 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

Also Published As

Publication number Publication date
DK1842550T3 (da) 2013-04-22
EP1842550A2 (en) 2007-10-10
EP1772152A2 (en) 2007-04-11
WO2004084927A2 (en) 2004-10-07
EP1462111A1 (en) 2004-09-29
ES2403074T3 (es) 2013-05-13
PT1842550E (pt) 2013-03-27
WO2004084927A3 (en) 2005-01-27
CA2518793A1 (en) 2004-10-07
EP1842550B1 (en) 2013-01-16
EP1772152A3 (en) 2007-06-27
US20060057154A1 (en) 2006-03-16
EP1842550A3 (en) 2008-12-10
EP1608391A2 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
GB0305941D0 (en) Composition
EP1666536A4 (en) CURABLE COMPOSITION
GB0302738D0 (en) Composition
GB0324918D0 (en) Composition
PT1842550E (pt) Composição para indução de imunotolerância
GB0324897D0 (en) Composition
HK1087034A1 (en) Actacid composition
GB0322033D0 (en) Composition
GB0305790D0 (en) Novel Composition
GB0318824D0 (en) Novel composition
MY145151A (en) Composition
EP1614717A4 (en) HARDENING COMPOSITION
GB0309317D0 (en) Composition
GB0324295D0 (en) Composition
GB0306312D0 (en) Composition
GB0326815D0 (en) Composition
GB0301869D0 (en) Composition
GB0218037D0 (en) Vaccine composition
GB0322975D0 (en) Composition
GB0312468D0 (en) Composition
GB0301560D0 (en) Composition
GB0320562D0 (en) Composition
GB0301669D0 (en) Composition
GB0320863D0 (en) Composition
GB0315769D0 (en) Immunigenic composition